Journal
PHARMACOGENOMICS
Volume 18, Issue 12, Pages 1119-1123Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2017-0054
Keywords
CYP2C19; CYP3A4; inflammation; pharmacogenetics; therapeutic drug monitoring; voriconazole
Categories
Ask authors/readers for more resources
How pharmacogenetics modulates the inhibitory effects of inflammation on voriconazole trough concentration (Cmin) remains unknown. In 29 recipients of allogeneic hematopoietic stem cell transplantation retrospectively studied, both a genetic score (which aggregated CYP2C19 and CYP3A genotypes) and inflammation significantly influenced voriconazole Cmin (n = 260). A trend toward (p = 0.03) a greater impact of inflammation in patients with the highest genetic score (corresponding to ultra-rapid metabolizers) was observed. Further researches are needed to confirm these data.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available